A Phase 1/2, Open Label, Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Dianhydrogalactitol (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Acronyms REPROVe
- Sponsors DelMar Pharmaceuticals
- 18 Oct 2017 Planned initiation date changed from 1 Dec 2017 to 1 Jan 2018.
- 18 Sep 2017 According to DelMar Pharmaceuticals media release, DelMar anticipates opening the VAL-083 REPROVe Trial for patient enrollment in early 2018.
- 18 Sep 2017 According to DelMar Pharmaceuticals media release, this trial has received IND Allowance from FDA.